クローン病における抗TNF-α治療 Anti-tumor necrosis factor therapy for Crohn's disease.:Anti-tumor necrosis factor therapy for Crohn's disease

この論文にアクセスする

この論文をさがす

著者

抄録

Tumor necrosis factor-alpha (TNFalpha), a proinflammatory cytokine, plays an important role in the pathogenesis of inflammatory bowel disease (IBD). Biotechnology agents including a chimeric monoclonal anti-TNF antibody (infliximab), a humanized monoclonal anti-TNF antibody (CDP 571), and a recombinant TNF receptor fusion protein (etanercept) have been used to inhibit TNFalpha activity. Controlled trials have demonstrated efficacy for infliximab in moderately to severely active Crohn's disease (CD) and fistulizing CD sufficient to justify recent U. S. Food and Drug Administration (FDA) approval. Additional trials have been completed in rheumatoid arthritis(RA). Similarly, preliminary controlled trials have suggested efficacy for CDP 571 in active CD. And etanercept is effective in patients with active CD similar to RA. Toxicities observed with anti-TNF therapies have included formation of human antichimeric antibodies (HACA) with associated acute and delayed hypersensitivity infusion reactions, human antihuman antibodies (HAHAs), and formation of autoantibodies with rare instances of drug-induced lupus. Several cases of non-Hodgkin's lymphoma also has been described. Future studies should evaluate optimal timing and duration of anti-TNF therapy, the utility of adjuvant medical treatments during anti-TNF therapy, and evaluate long-term safety and efficacy of the various anti-TNF agents.

収録刊行物

  • Drug delivery system

    Drug delivery system 17(1), 42-49, 2002-01-10

    日本DDS学会

参考文献:  21件中 1-21件 を表示

各種コード

  • NII論文ID(NAID)
    10008132037
  • NII書誌ID(NCID)
    AN10084591
  • 本文言語コード
    JPN
  • 資料種別
    REV
  • ISSN
    09135006
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ